Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance

Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance

Submitted by admin on December 23, 2019 - 11:52pm
Source: 
BioSpace
News Tags: 
Pfizer
Theravance
JAK inhibitors
Headline: 
Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance
snippet: 

Pfizer handed over $10 million in upfront money and dangled a potential $240 million more if the program hits certain development and sales milestones.

Do Not Allow Advertisers to Use My Personal information